DEA's Telemedicine Special Registration Final Rule Reaches White House Review

The long-delayed federal framework for prescribing controlled substances by telehealth has moved a step closer. On August 25, 2026, the Drug Enforcement Administration (DEA) sent its final Special Registrations for Telemedicine rule to the White House Office of Information and Regulatory Affairs (OIRA), the review office inside the Office of Management and Budget that clears significant federal regulations before they publish. The submission is the last major procedural gate before a rule can become final, and it arrives with a hard deadline in view: the pandemic-era flexibilities that currently let clinicians prescribe controlled medications online without an in-person visit are set to lapse on December 31, 2026.

What just happened

The rule at OIRA carries Regulatory Identification Number (RIN) 1117-AB40, the same identifier the DEA used for its January 2025 proposal. OIRA review is a required checkpoint for economically significant rules and commonly runs up to 90 days, though it can be shorter or longer. The text under review is not released to the public while OIRA evaluates it, so the exact contours of the final rule are not yet known. What is public is the proposed rule the DEA issued on January 17, 2025, whose comment period closed on March 18, 2025. The final rule can adopt, revise, or drop elements of that proposal.

The DEA's regulatory agenda anticipates final action in November 2026. That is a forecast, not a scheduled publication date, and the timing depends on how the OIRA review proceeds.

Why a special registration exists at all

Under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, a controlled substance generally cannot be prescribed online without at least one in-person medical evaluation, and Congress directed the DEA to create a special registration process that would allow telemedicine prescribing in defined circumstances. That special registration was never built out. During the COVID-19 public health emergency the in-person requirement was waived, and after the emergency ended the DEA and the Department of Health and Human Services extended the waiver repeatedly rather than let a prescribing cliff hit patients. The rule now at OIRA is the DEA's attempt to replace those temporary extensions with a permanent framework.

The three registration types in the proposal

As proposed in January 2025, the framework would establish three distinct registrations. The final rule may change these, but the proposal describes them as follows:

• Telemedicine Prescribing Registration: for qualified clinician practitioners (physicians and certain board-certified mid-level practitioners) to prescribe Schedule III to V controlled substances via telemedicine.
• Advanced Telemedicine Prescribing Registration: for specialized practitioners (for example psychiatrists, hospice and palliative care physicians, and other listed specialties) to prescribe Schedule II to V controlled substances via telemedicine.
• Telemedicine Platform Registration: for covered online telemedicine platforms, acting as platform practitioners, tied to the dispensing of Schedule II to V controlled substances.

What the proposal would require of prescribers

The proposed conditions are substantial, which is part of why the rule has taken years and drawn heavy comment. Key requirements in the proposal include:

• A separate State Telemedicine Registration for each state in which a patient receives treatment, with limited exemptions.
• PDMP checks before prescribing. The proposal describes an interim requirement to check the prescription drug monitoring programs of the patient's state, the prescriber's state, and states with reciprocity, and a broader nationwide PDMP check with a delayed (roughly three-year) effective date.
• Electronic prescribing for controlled substances (EPCS) for prescriptions issued under the special registration.
• Centralized recordkeeping at the registered location, plus reporting and other compliance obligations.
• A specific condition for Schedule II prescriptions to minors, under which a parent or guardian would need to be present.

Why the December 31, 2026 deadline matters

The current ability to prescribe controlled substances via telehealth without a prior in-person visit rests on a temporary extension. In its fourth extension, effective January 1, 2026 through December 31, 2026, the DEA and HHS kept the flexibilities in place for Schedule II to V medications and stated that the extension was meant to give the DEA time to promulgate a final set of regulations and to let providers come into compliance. According to the Alliance for Connected Care's tracking of the rulemaking, without further action telemedicine prescribing of controlled substances would be restricted beginning January 1, 2027. That is the practical reason the November 2026 target and the OIRA review are drawing close attention from telehealth clinicians.

What OIRA review does and does not settle

Reaching OIRA is a meaningful milestone, but it is not the finish line. OIRA can clear the rule, return it to the DEA for changes, or the agency can withdraw it. Even after OIRA concludes, the rule must be published, and a final rule can carry its own effective and compliance dates that phase requirements in over time. Nothing about who can prescribe, or how, changes at the moment the rule lands at OIRA. Until a final rule takes effect, the December 31, 2026 flexibilities remain the operative rules for controlled-substance telehealth prescribing.

What this means for telehealth patients and clinicians

This is general information, not medical or legal advice. For patients who rely on telehealth for medications such as ADHD stimulants (Schedule II) or buprenorphine for opioid use disorder, the near-term status quo holds through the end of 2026. A few reasonable steps while the process plays out:

• Ask your prescriber how they plan to handle any transition if a final rule adds new registration or in-person requirements to your medication.
• Do not stop or change a prescribed controlled medication on your own based on a pending rule. Coordinate any change with your licensed clinician.
• Watch for the DEA's final rule and its stated effective and compliance dates, which is where any binding change would actually appear.
• Keep in mind that the version now under review is not public, so specific requirements described here reflect the January 2025 proposal and could change.